Concomitant use w/ fluoxetine or fluvoxamine, dextromethorphan or sympathomimetics. At least 14 days should elapse between discontinuation of rasagiline & initiation of treatment w/ fluoxetine or fluvoxamine. Regularly monitor patients for the development of impulse control disorders (eg, compulsions, obsessive thoughts, pathological gambling, increased libido, hypersexuality, impulsive behaviour & compulsive spending or buying). Not recommended in concomitant use w/ dextromethorphan or sympathomimetics eg, those present in nasal & oral decongestants or cold medicinal products containing ephedrine or pseudoephedrine. May increase risk of melanoma in patients w/ longer duration of exposure &/or higher cumulative dose. Evaluate any suspicious skin lesion. Mild hepatic impairment. Avoid use in moderate hepatic impairment. Discontinue treatment if patient progresses from mild to moderate hepatic impairment. May cause daytime drowsiness, somnolence & falling asleep during activities of daily living. Possible additive effects w/ sedatives, alcohol, CNS depressants (eg, benzodiazepines, antipsychotics, antidepressants), ciprofloxacin. Do not drive, operate machinery, or work at heights during treatment. Pregnancy & lactation. Childn & adolescent.
Sign Out
